Patents Represented by Attorney, Agent or Law Firm Dan L. Wood
  • Histamine H3 receptor agents, preparation and therapeutic uses
    Patent number: 8178528
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine—H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: May 15, 2012
    Assignee: Eli Lilly and Company
    Inventors: Philip Arthur Hipskind, Takako Takakuwa, Cynthia Darshini Jesudason, Robert Alan Gadski, William Joseph Hornback, Richard Todd Pickard, Lisa Selsam Beavers
  • Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Patent number: 8153807
    Abstract: The present invention discloses novel compounds of Formula I: (I) having 11-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11-HSD type 1 activity.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: April 10, 2012
    Assignee: Eli Lilly and Company
    Inventors: Julie Kay Bush, Marvin Martin Hansen, Renhua Li, Thomas Edward Mabry, Nancy June Snyder, Owen Brendan Wallace, Yanping Xu
  • Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Patent number: 8148534
    Abstract: The present invention discloses novel compounds of Formula I: (I) possessing 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11?-HSD type 1 activity.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: April 3, 2012
    Assignee: Eli Lilly and Company
    Inventors: Renhua Li, Owen Brendan Wallace, Yanping Xu
  • Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Patent number: 8088776
    Abstract: The present invention discloses novel compounds of Formula I: possessing 11 ?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 ?-HSD type 1 activity.
    Type: Grant
    Filed: April 19, 2007
    Date of Patent: January 3, 2012
    Assignee: Eli Lilly and Company
    Inventors: Thomas Daniel Aicher, Zhaogen Chen, Ronald Jay Hinklin, Gary Alan Hite, Alexei Pavlovych Krasutsky, Renhua Li, Jefferson Ray McCowan, Ashraf Saeed, Nancy June Snyder, James Lee Toth, Owen Brendan Wallace, Leonard Larry Winneroski, Jr., Yanping Xu, Jeremy Schulenburg York
  • Glucagon receptor antagonists, preparation and therapeutic uses
    Patent number: 8084489
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have glucagon receptor antagonist or inverse agonist activity, as well as methods of using these compounds and intermediates and methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising N compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: December 27, 2011
    Assignee: Eli Lilly and Company
    Inventors: Mark Donald Chappell, Scott Eugene Conner, Allie Edward Tripp, Guoxin Zhu
  • Glucagon receptor antagonists, preparation and therapeutic uses
    Patent number: 8076374
    Abstract: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: December 13, 2011
    Assignee: Eli Lilly and Company
    Inventors: Mark Donald Chappell, Scott Eugene Conner, Philip Arthur Hipskind, Jason Eric Lamar, Guoxin Zhu
  • Histamine H3 receptor agents, preparation and therapeutic uses
    Patent number: 8008301
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine—H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: August 30, 2011
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Terry Patrick Finn, Robert Alan Gadski, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Richard Todd Pickard, Takako Takakuwa, Grant Mathews Vaught
  • Histamine H3 receptor agents, preparation and therapeutic uses
    Patent number: 8008296
    Abstract: The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. (Formula I).
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: August 30, 2011
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Robert Alan Gadski, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Richard Todd Pickard, Takako Takakuwa, Grant Mathews Vaught
  • Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Patent number: 7998999
    Abstract: The present invention discloses novel compounds of Formula I: having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: August 16, 2011
    Assignee: Eli Lilly and Company
    Inventors: Owen Brendan Wallace, Yanping Xu, Nancy June Snyder, Jeremy Schulenburg York, Alexei Pavlovych Krasutsky
  • Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Patent number: 7994176
    Abstract: The present invention discloses novel compounds of Formula I: having 11 Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11 Beta-HSD type 1 activity.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: August 9, 2011
    Assignee: Eli Lilly and Company
    Inventors: Renhua Li, Thomas Edward Mabry, Owen Brendan Wallace, Leonard Larry Winneroski, Jr., Yanping Xu
  • Glucagon receptor antagonists, preparation and therapeutic uses
    Patent number: 7989457
    Abstract: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: August 2, 2011
    Assignee: Eli Lilly and Company
    Inventors: Mark Donald Chappell, Scott Eugene Conner, Isabel Cristina Gonzalez Valcarcel, Jason Eric Lamar, Jianke Li, Julie Sue Moyers, Rebecca Anne Owens, Allie Edward Tripp, Guoxin Zhu
  • Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Patent number: 7981918
    Abstract: The present invention discloses novel compounds of Formula (I): having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: July 19, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Daniel Aicher, Peter Biagio Anzeveno, Renhua Li, Alexei Pavlovych Krasutsky, Thomas Edward Mabry, Ashraf Saeed, Nancy June Snyder, Hongqi Tian, Owen Brendan Wallace, Leonard Larry Winneroski, Yanping Xu
  • Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Patent number: 7968585
    Abstract: The present invention discloses novel compounds of Formula (I): having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: June 28, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Edward Mabry, Owen Brendan Wallace, Yanping Xu, Nancy June Snyder, Leonard Larry Winneroski, Jr.
  • Pyrrolidine derivatives as histamine H3 receptor antagonists
    Patent number: 7951826
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: May 31, 2011
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Robert Alan Gadski, Philip Arthur Hipskind, Cynthia Darshini Jesudason, Richard Todd Pickard, Freddie Craig Stevens, Takako Takakuwa
  • Tetrahydrocarbazole derivatives useful as androgen receptor modulators
    Patent number: 7935722
    Abstract: The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of formula (I).
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: May 3, 2011
    Assignee: Eli Lilly and Company
    Inventors: Kevin Robert Fales, Jonathan Edward Green, Prabhakar Kondaji Jadhav, Donald Paul Matthews, David Andrew Neel, Edward C R Smith
  • Histamine H3 receptor antagonists, preparation and therapeutic uses
    Patent number: 7902191
    Abstract: The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases.
    Type: Grant
    Filed: February 22, 2005
    Date of Patent: March 8, 2011
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Robert Alan Gadski, Philip Arthur Hipskind, Cynthia Darshini Jesudason, Karen Lynn Lobb, Richard Todd Pickard, Craig William Lindsley
  • Glucagon receptor antagonists, preparation and therapeutic uses
    Patent number: 7863329
    Abstract: The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: January 4, 2011
    Assignee: Eli Lilly and Company
    Inventors: Jianke Li, Guoxin Zhu
  • Histamine H3 receptor inhibitors, preparation and therapeutic uses
    Patent number: 7846950
    Abstract: The present invention provides novel compounds with histamine-H3 receptor antagonist or inverse agonist activity. In particular, the invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and intermediates and methods for making these compounds. The invention provides methods of using compounds and pharmaceutical compositions to treat obesity, cognitive deficiences, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: December 7, 2010
    Assignee: Eli Lilly and Company
    Inventors: Cynthia Darshini Jesudason, Freddie Craig Stevens
  • Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Patent number: 7834194
    Abstract: The present invention provides compounds of formula I that are useful as potent and selective inhibitors of 11-beta hydroxysteroid dehydrogenase 1. The present invention further provides a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. In addition, the present invention provides compositions comprising compounds of formula I for the treatment of metabolic syndrome, diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, other symptoms associated with hyperglycemia, and related disorders. Formula (I) wherein, R0 is (II), or (III) G1 is methylene or ethylene; L is a divalent linking group selected from —(C1-C4) alkylene-, —S—, —CH(OH)—, or —O—; A is methylene, —S—, —O—, or —NH—; and the other substituents are as defined in the claims.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: November 16, 2010
    Assignee: Eli Lilly and Company
    Inventors: Thomas Daniel Aicher, Mark Joseph Chicarelli, Ronald Jay Hinklin, Hongqi Tian, Owen Brendan Wallace
  • Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Patent number: 7829582
    Abstract: The present invention discloses novel compounds of Formula I: having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: November 9, 2010
    Assignee: Eli Lilly and Company
    Inventors: Owen Brendan Wallace, Yanping Xu, Jeremy Schulenburg York